Cumulative duration of drug exposure* | ||||||
---|---|---|---|---|---|---|
Less than 5 years | 5–10 years | More than 10 years | ||||
CCB cohort | AHT cohort | CCB cohort | AHT cohort | CCB cohort | AHT cohort | |
Cancer rates (per 1000 person-years) | 25.9 | 13.8 | 10.53 | 8.75 | 4.59 | 3.08 |
Number of cancers | 10 449 | 6917 | 3441 | 2400 | 705 | 437 |
Number of person-years | 403 881 | 502 788 | 326 639 | 274 173 | 153 656 | 141 840 |
Crude HR (95% CI) | 1.85 (1.79 to 1.90) | 1.00 (reference) | 1.33 (1.27 to 1.40) | 1.00 (reference) | 1.43 (1.27 to 1.61) | 1.00 (reference) |
Adjusted HR (95% CI) | 0.88 (0.85 to 0.91)† | 1.00 (reference) | 0.98 (0.93 to 1.04) | 1.00 (reference) | 1.11 (0.98 to 1.27) | 1.00 (reference) |
*Duration of CCB exposure estimated using dates of first and last utilisation within the period at risk; same rule applied to the AHT cohort.
†p<0.001. HR obtained from multivariate Cox proportional hazard analyses including age at index date, gender, smoking status, body mass index, alcohol consumption, diagnoses of diabetes, hypertension, arrhythmia, angina or heart failure, and use of statins or aspirin.